Eli Lilly Set for Key Monday After New Weight-Loss Drug Data
Eli Lilly heads into the U.S. pre-market Monday facing a fresh test of its trillion-dollar market cap after dropping new data on wider benefits from its upcoming obesity drugs. Shares ended Friday at $1,131.42, gaining 0.55%. The S&P 500 ETF lost 2.6%. The Health Care Select Sector SPDR ETF picked up 0.6% in the last quoted session.
